Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TDF Vaginal Ring in Sexually Active Women
NCT02762617Phase 1Terminated
- Start
- Feb 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial in human immunodeficiency virus infection (HIV) comparing TDF IVR group with Placebo IVR group (2 arms). Primary endpoint: Proportion of women in each arm experiencing adverse events (AEs) at 84 days. Started Feb 2017; status: terminated.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02762617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762617.